» Articles » PMID: 22463776

Short Communication: Initiation of an Abacavir-containing Regimen in HIV-infected Adults is Associated with a Smaller Decrease in Inflammation and Endothelial Activation Markers Compared to Non-abacavir-containing Regimens

Overview
Publisher Mary Ann Liebert
Date 2012 Apr 3
PMID 22463776
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Abacavir has been associated with myocardial infarction in several studies. This may be related to inflammation and endothelial cell activation. We compared changes in inflammation and endothelial activation markers between antiretroviral-naive adults initiating zidovudine, lamivudine, abacavir, and nonnucleoside reverse transcriptase inhibitor (NNRTI) or this regimen without abacavir. Changes in soluble tumor necrosis factor receptors-I, -II (sTNFR-I, -II), high sensitivity C-reactive protein, and soluble vascular cell adhesion molecule-1 (sVCAM-1) from baseline (pre-ART) to a second time point about 24 weeks after initiating antiretroviral therapy (ART) were compared between groups using multivariable linear regression. A total of 37 met eligibility criteria; 12 received abacavir. The median (interquartile range) age was 37 years (27-45). Most were men (32/37), African-American (15/37), or white (15/37). The median nadir CD4(+) and baseline HIV-1 RNA were 230 cells/mm(3) (180-301) and 82,642 copies/ml (34,400-204,703). In all, 15/30 smoked, 7/37 had hypertension, 1/37 had diabetes, and 1/37 had hyperlipidemia. None had coronary or renal disease. Changes in CD4(+) and HIV-1 RNA level and timing of stored samples with regard to ART initiation were not different between groups. In univariable analysis, log transformed percent change in sTNFR-I (p=0.05) and -II (p=0.04) showed significant between-group differences and trended toward significance for sVCAM-1 (p=0.08). These markers decreased less in the abacavir group. After adjustment for confounders, significantly less decrease for sTNFR-II and sVCAM-1 was seen for those receiving the abacavir-containing regimen. When taken with an NNRTI, abacavir induced a smaller decrease in inflammation biomarkers in this cohort, suggesting a possible proinflammatory effect of this nucleoside analogue.

Citing Articles

HIV Infection, Antiretroviral Drugs, and the Vascular Endothelium.

Kanmogne G Cells. 2024; 13(8.

PMID: 38667287 PMC: 11048826. DOI: 10.3390/cells13080672.


Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection.

Chan P, Yoon B, Colby D, Kroon E, Sacdalan C, Sriplienchan S Clin Infect Dis. 2022; 76(3):e718-e726.

PMID: 35687498 PMC: 9907536. DOI: 10.1093/cid/ciac466.


Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?.

Tincati C, Mondatore D, Bai F, Monforte A, Marchetti G Open Forum Infect Dis. 2020; 7(9):ofaa340.

PMID: 33005694 PMC: 7513927. DOI: 10.1093/ofid/ofaa340.


Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.

Dorjee K, Choden T, Baxi S, Steinmaus C, Reingold A Int J Antimicrob Agents. 2018; 52(5):541-553.

PMID: 30040992 PMC: 7791605. DOI: 10.1016/j.ijantimicag.2018.07.010.


Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.

Dorjee K, Baxi S, Reingold A, Hubbard A BMC Infect Dis. 2017; 17(1):708.

PMID: 29078761 PMC: 5660446. DOI: 10.1186/s12879-017-2808-8.


References
1.
Chung N, Lydakis C, Belgore F, Li-Saw-Hee F, Blann A, Lip G . Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart. 2003; 89(12):1411-5. PMC: 1767979. DOI: 10.1136/heart.89.12.1411. View

2.
Palella Jr F, Gange S, Benning L, Jacobson L, Kaplan R, Landay A . Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS. 2010; 24(11):1657-65. PMC: 3514460. DOI: 10.1097/QAD.0b013e3283389dfa. View

3.
Durand M, Sheehy O, Baril J, LeLorier J, Tremblay C . Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr. 2011; 57(3):245-53. DOI: 10.1097/QAI.0b013e31821d33a5. View

4.
Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A . Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010; 170(14):1228-38. DOI: 10.1001/archinternmed.2010.197. View

5.
Bedimo R, Westfall A, Drechsler H, Vidiella G, Tebas P . Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011; 53(1):84-91. DOI: 10.1093/cid/cir269. View